Source: International Congress 2019 – Novel findings from asthma clinical trials
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Upham (Brisbane, Australia), D. Jackson (London, United Kingdom), P. Barker (Gaithersburg, United States of America), P. Newbold (Gaithersburg, United States of America), W. Cook (Gaithersburg, United States of America). Baseline predictors of being exacerbation-free during 2 years of benralizumab treatment. 5337

Member's Comments

No comment yet.

Related content which might interest you: Baseline differences in incident COPD patients who do and do not exacerbate in 2 years of follow up in the UK Source: Annual Congress 2010 - Prevalence and incidence of asthma and COPD Year: 2010 COPD patients under 50 years of age: 4-year follow-up in the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 Severe asthma outcomes over 18-months treatment with mepolizumab, and comorbidities in non-responders. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Four years follow-up of exacerbations in a cohort of COPD patients: 1 year interim results (EXACO study) Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Outcomes of level 1 Covid-19 inpatients at six months Source: Virtual Congress 2021 – COVID - 19 epidemiology Year: 2021 Long-term predictors of lung function decrease in asthmatics: a 9 year follow-up study Source: Eur Respir J 2006; 28: Suppl. 50, 145s Year: 2006 Treatment outcome and one year follow-up status of patients treated under DOTS category II Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Pharmacoeconomic evaluation of COPD: A 1 year follow-up study Source: Annual Congress 2010 - Influence of delivery of care on outcome parameters: therapy is more than medication prescription Year: 2010 Clinical indicators of treatment response to Mepolizumab at 12 weeks Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study Source: Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020 Year: 2021 Change of T2-markers in patients with severe uncontrolled asthma treated by monoclonal antibodies: 1 yr follow up Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Clinical outcome of adult onset asthma in a 15 year follow-up Source: Virtual Congress 2020 – Risk factors for chronic lung diseases Year: 2020 Asthma control and quality of life in asthmatic patients treated for 6 months with FDC Budesonide/Formoterol - BOREAS study: a subgroup analysis in patients with comorbidities Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Predictors of asthma symptom remission after five years of age Source: Annual Congress 2011 - Paediatric epidemiology: predicting outcomes of wheeze, antenatal growth, early life exposures and outcome of premature birth Year: 2011 Outcomes over the first two years of treatment with mepolizumab in severe asthma Source: Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021 Year: 2021 Who win? Spirometry versus symptoms for predicting the longitudinal outcomes in COPD patients – 10 years observation Source: Annual Congress 2011 - Clinical parameters in airway diseases Year: 2011 Asthma; gender differences in incidence and remission from 10 to 16 years? Source: Annual Congress 2010 - Risk factors for allergic diseases in children Year: 2010 Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study Source: Eur Respir J 2003; 22: Suppl. 45, 578s Year: 2003 Primary ciliary dyskinesia: 3 years of follow-up of a cohort of patients under treatment Source: Annual Congress 2009 - Bacterial infections of upper and lower respiratory tract in childhood Year: 2009 Ambrisentan therapy for PAH patients with WHO class II symptoms: one year follow-up. Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008